Literature DB >> 17639044

Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor.

Takashi Suzuki1, Akio Inoue, Yasuhiro Miki, Takuya Moriya, Jun-ichi Akahira, Takanori Ishida, Hisashi Hirakawa, Yuri Yamaguchi, Shin-ichi Hayashi, Hironobu Sasano.   

Abstract

Early growth responsive gene 3 (EGR3) is a zinc-finger transcription factor and plays important roles in cellular growth and differentiation. We recently demonstrated estrogen-mediated induction of EGR3 in breast carcinoma cells. However, EGR3 has not yet been examined in breast carcinoma tissues and its significance remains unknown. Therefore, in this study, we examined biological functions of EGR3 in the breast carcinoma by immunohistochemistry, in vitro study, and nude mouse xenograft model. EGR3 immunoreactivity was detected in carcinoma cells in 99 (52%) out of 190 breast carcinoma tissues and was associated with the mRNA level. EGR3 immunoreactivity was positively associated with lymph node status, distant metastasis into other organs, estrogen receptor alpha, or EGR3 immunoreactivity in asynchronous recurrent lesions in the same patients, and was negatively correlated with tubule formation. EGR3 immunoreactivity was significantly associated with an increased risk of recurrence and adverse clinical outcome by both uni- and multivariate analyses. Egr3-expressing transformant cell lines derived from MCF-7 Tet-Off cells (Eg-10 and Eg-11) significantly enhanced the migration and invasion properties according to the treatment of doxycyclin, but did not significantly change the cell proliferation. Moreover, Eg-11 cells injected into athymic mice irregularly invaded into the adjacent peritumoral tissues, although Clt-7, which was stably transfected with empty vector as a control, demonstrated a well-circumscribed tumor. Eg-11 cells were significantly associated with invasive components and less tubule formation in the xenograft model. These results suggest that EGR3 plays an important role in estrogen-meditated invasion and is an independent prognostic factor in breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639044     DOI: 10.1677/ERC-06-0005

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  18 in total

1.  EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin.

Authors:  Joerg Kumbrink; Kathrin H Kirsch; Judith P Johnson
Journal:  J Cell Biochem       Date:  2010-09-01       Impact factor: 4.429

2.  The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells.

Authors:  Vladimír Cermák; Jan Kosla; Jirí Plachý; Katerina Trejbalová; Jirí Hejnar; Michal Dvorák
Journal:  Cell Mol Life Sci       Date:  2010-05-28       Impact factor: 9.261

3.  Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells.

Authors:  Zhong-Dong Wang; Fan-Yong Qu; Yuan-Yuan Chen; Zhang-Shen Ran; Hai-Yan Liu; Hai-Dong Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Jan.       Impact factor: 3.066

4.  Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2.

Authors:  Joerg Kumbrink; Kathrin H Kirsch
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

5.  Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.

Authors:  Lee Shaashua; Maytal Shabat-Simon; Rita Haldar; Pini Matzner; Oded Zmora; Moshe Shabtai; Eran Sharon; Tanir Allweis; Iris Barshack; Lucile Hayman; Jesusa Arevalo; Jeffrey Ma; Maya Horowitz; Steven Cole; Shamgar Ben-Eliyahu
Journal:  Clin Cancer Res       Date:  2017-05-10       Impact factor: 12.531

6.  TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.

Authors:  Ken-ichi Takayama; Kuniko Horie-Inoue; Takashi Suzuki; Tomohiko Urano; Kazuhiro Ikeda; Tetsuya Fujimura; Satoru Takahashi; Yukio Homma; Yasuyoshi Ouchi; Satoshi Inoue
Journal:  Mol Endocrinol       Date:  2012-03-28

7.  Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells.

Authors:  Andrei P Drabovich; Maria P Pavlou; Christina Schiza; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2016-04-11       Impact factor: 5.911

8.  Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer.

Authors:  Seung-Hyun Shin; Iljin Kim; Jae Eun Lee; Mingyu Lee; Jong-Wan Park
Journal:  Oncogene       Date:  2020-08-14       Impact factor: 9.867

9.  Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.

Authors:  Gianpiero Di Leva; Claudia Piovan; Pierluigi Gasparini; Apollinaire Ngankeu; Cristian Taccioli; Daniel Briskin; Douglas G Cheung; Brad Bolon; Laura Anderlucci; Hansjuerg Alder; Gerard Nuovo; Meng Li; Marilena V Iorio; Marco Galasso; Ramasamy Santhanam; Santhanam Ramasamy; Guido Marcucci; Danilo Perrotti; Kimerly A Powell; Anna Bratasz; Michela Garofalo; Kenneth P Nephew; Carlo M Croce
Journal:  PLoS Genet       Date:  2013-03-07       Impact factor: 5.917

10.  Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer.

Authors:  Rebecca Pio; Zhenyu Jia; Veronique T Baron; Dan Mercola
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.